The Food and Drug Administration yesterday published draft guidance to promote clinical studies to increase drug safety information for pregnant and nursing women and their providers. One document provides recommendations to facilitate studies to inform drug labeling for breastfeeding women. The other document includes recommendations on how to design studies to assess pregnancy outcomes in women taking FDA-regulated drugs and biological products during pregnancy. FDA said the recommendations are consistent with those of the task force created by the 21st Century Cures Act to identify and report on drug safety research and knowledge gaps for pregnant and nursing women. The agency will accept comments on the draft guidance through July 8.

Related News Articles

Headline
HHS is soliciting input and will meet with vendors Aug. 7-8 to spur innovation in developing new technologies and products to save lives and improve health…
Headline
The Centers for Disease Control and Prevention is working with the U.S. Embassy in the Democratic Republic of the Congo to preposition staff in Goma to rapidly…
Headline
The World Health Organization today declared the Ebola virus disease outbreak in the Democratic Republic of the Congo a public health emergency of…
Headline
The Centers for Medicare…
Headline
CMS anticipates releasing later this summer the feedback it received on potential methodology changes to the overall hospital quality star ratings, the agency…
Headline
The Health Resources and Services Administration yesterday recognized 10 states whose critical access hospitals had the highest quality reporting rates and…